Cantor Fitzgerald Reaffirms Neutral Rating on Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY – Get Free Report)Research analysts at Cantor Fitzgerald reiterated a “neutral” rating on the stock in a research note issued to investors on Monday, Benzinga reports. They currently have a $45.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 5.14% from the company’s current price.

Other analysts have also recently issued reports on the company. StockNews.com lowered their rating of Bristol-Myers Squibb from a “strong buy” rating to a “buy” rating in a research report on Thursday, June 27. Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1. BMO Capital Markets lowered their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26. Finally, Barclays lowered their price target on shares of Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 10. One investment analyst rated the stock a sell, thirteen rated it a hold, and four gave the company a buy rating. The company has an average rating of “Hold” and an average price target of $58.40 according to MarketBeat.com.

See our latest analysis of BMY

Bristol-Myers Squibb shares rose 0.4%

NYSE:BMY shares were up $0.16 during afternoon trading on Monday, to $42.80. 3,069,942 shares of the company were traded, compared to its average volume of 15,629,795. The stock has a 50-day moving average price of $41.68 and a 200-day moving average price of $46.99. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $65.38. The stock has a market capitalization of $86.76 billion, a P/E ratio of -13.81, a P/E/G ratio of 15.55 and a beta of 0.44. The company has a current ratio of 1.11, a current ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings data on Thursday, April 25. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of (4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period last year, the company earned $2.05 EPS. The company’s revenue for the quarter increased by 4.7% compared to the same quarter last year. Equity research analysts, on average, forecast that Bristol-Myers Squibb will post 0.55 earnings per share for the current year.

Bristol-Myers Squibb Institutional Trading

Hedge funds have recently made changes to their positions in stocks. Traynor Capital Management Inc. increased its holdings in shares of Bristol-Myers Squibb by 2.8% in the first quarter. Traynor Capital Management Inc. now owns 7,672 shares of the biopharmaceutical company’s stock worth $416,000 after acquiring an additional 207 shares in the last quarter. Fulton Breakefield Broenniman LLC increased its holdings in shares of Bristol-Myers Squibb by 4.6% in the fourth quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 209 shares in the last quarter. Accurate Wealth Management LLC increased its holdings in shares of Bristol-Myers Squibb by 4.0% in the first quarter. Accurate Wealth Management LLC now owns 5,612 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 216 shares in the last quarter. Newbridge Financial Services Group Inc. increased its position in shares of Bristol-Myers Squibb by 12.8% in the first quarter. Newbridge Financial Services Group Inc. now owns 1,910 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 216 shares in the last quarter. Finally, Bfsg LLC increased its holdings in Bristol-Myers Squibb by 24.4% in the first quarter. Bfsg LLC now owns 1,120 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 220 shares in the last quarter. 76.41% of the shares are owned by institutional investors.

About Bristol-Myers Squibb

(Download the free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunological, fibrotic, and neurologic diseases. The company’s products include Eliquis for the reduction of stroke/systemic embolism in nonvalvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, gastric, and esophageal cancers; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

Get daily news and ratings for Bristol-Myers Squibb – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Bristol-Myers Squibb and related companies in MarketBeat.com’s FREE daily newsletter.